“…The small surface contact area enables treatment with high flexibility which is beneficial for skin cancer therapy while minimizing side effects by limiting exposure to the disease area. Additive or synergistic efficacies of cold gas plasmas have been described before, for example, in combination with doxorubicin [52] , [53] , [54] , cisplatin [55] , [56] , [57] , [58] , methotrexate [59] , imiquimod [50] , gemcitabine [60] , [61] , olaparib [62] , ADDA5 [63] , cyclophosphamide [64] , paclitaxel [59] , [65] , [66] , [67] , and temozolomide [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] across different tumor cell types in vitro and partially also in vivo . Therefore, systemic drug treatment combined with local cold gas plasma treatment may provide a viable strategy to achieve improved anti-tumor efficacies with reduced systemic side effects, provided a local tumor treatment is achievable, as in skin cancer.…”